13D Filing: Broadfin Capital and Novelion Therapeutics Inc. (NVLN)

Page 9 of 9

Page 9 of 9 – SEC Filing

Exhibit A

AGREEMENT

The undersigned agree that
this Schedule 13D Amendment, dated March 20, 2018, relating to the Common Shares, without par value of Novelion Therapeutics Inc.
shall be filed on behalf of the undersigned.

March 20, 2018
(Date)
BROADFIN CAPITAL, LLC
By: /s/ Kevin Kotler
Kevin Kotler, Managing Member
KEVIN KOTLER
/s/ Kevin Kotler
BROADFIN HEALTHCARE MASTER FUND, LTD.
By:   /s/ Kevin Kotler
Kevin Kotler, Director

Follow Novelion Therapeutics Inc. (NASDAQ:NVLN)

Page 9 of 9